risperidone has been researched along with Neoplasms in 7 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of delirium often includes haloperidol." | 9.34 | Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020) |
| "Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission." | 9.16 | Treatment of delirium with risperidone in cancer patients. ( Kato, M; Kishi, Y; Okuyama, T; Thurber, S, 2012) |
| "The clinical benefit of perospirone for treatment of delirium in patients with advanced cancer is not sufficiently clear." | 8.12 | Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings. ( Inoue, S; Maeda, I; Ogawa, A; Terada, S; Yamada, N; Yoshiuchi, K, 2022) |
| "Oral risperidone was given once a day (0." | 5.43 | Association of the Clinical Subtype and Etiology for Delirium with the Outcome after Risperidone Monotherapy in Patients Having Cancer. ( Inoue, K; Matsuda, Y; Nakao, Y; Takemura, M; Tsuruta, R; Yabe, M, 2016) |
| "Treatment of delirium often includes haloperidol." | 5.34 | Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020) |
| "Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission." | 5.16 | Treatment of delirium with risperidone in cancer patients. ( Kato, M; Kishi, Y; Okuyama, T; Thurber, S, 2012) |
| "The clinical benefit of perospirone for treatment of delirium in patients with advanced cancer is not sufficiently clear." | 4.12 | Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings. ( Inoue, S; Maeda, I; Ogawa, A; Terada, S; Yamada, N; Yoshiuchi, K, 2022) |
| "To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS)." | 3.83 | Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study. ( Goya, S; Kai, T; Kanemura, S; Kashiwagi, Y; Maeda, I; Matsuda, Y; Nakajima, S; Okamoto, Y; Taira, T; Takei, K; Tanimukai, H; Tokoro, A; Tokuyama, M; Tsujimoto, H; Tsujio, I; Watanabe, M, 2016) |
| "Oral risperidone was given once a day (0." | 1.43 | Association of the Clinical Subtype and Etiology for Delirium with the Outcome after Risperidone Monotherapy in Patients Having Cancer. ( Inoue, K; Matsuda, Y; Nakao, Y; Takemura, M; Tsuruta, R; Yabe, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Inoue, S | 1 |
| Maeda, I | 2 |
| Ogawa, A | 1 |
| Yoshiuchi, K | 1 |
| Terada, S | 1 |
| Yamada, N | 1 |
| van der Vorst, MJDL | 1 |
| Neefjes, ECW | 1 |
| Boddaert, MSA | 1 |
| Verdegaal, BATT | 1 |
| Beeker, A | 1 |
| Teunissen, SCC | 1 |
| Beekman, ATF | 1 |
| Wilschut, JA | 1 |
| Berkhof, J | 1 |
| Zuurmond, WWA | 1 |
| Verheul, HMW | 1 |
| Matsuda, Y | 2 |
| Nakao, Y | 1 |
| Yabe, M | 1 |
| Tsuruta, R | 1 |
| Takemura, M | 1 |
| Inoue, K | 1 |
| Tanimukai, H | 1 |
| Tsujimoto, H | 1 |
| Tokoro, A | 1 |
| Kanemura, S | 1 |
| Watanabe, M | 1 |
| Tsujio, I | 1 |
| Takei, K | 1 |
| Nakajima, S | 1 |
| Taira, T | 1 |
| Tokuyama, M | 1 |
| Kai, T | 1 |
| Okamoto, Y | 1 |
| Goya, S | 1 |
| Kashiwagi, Y | 1 |
| Kishi, Y | 1 |
| Kato, M | 1 |
| Okuyama, T | 1 |
| Thurber, S | 1 |
| Ito, H | 1 |
| Harada, D | 1 |
| Hayashida, K | 1 |
| Ishino, H | 1 |
| Nakayama, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer[NCT01539733] | 101 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for risperidone and Neoplasms
| Article | Year |
|---|---|
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Neoplasms; Olanzapine; | 2020 |
Treatment of delirium with risperidone in cancer patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Hallucinations; Humans; Male; Middl | 2012 |
5 other studies available for risperidone and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings.
Topics: Aged; Antipsychotic Agents; Delirium; Humans; Isoindoles; Neoplasms; Psycho-Oncology; Risperidone; T | 2022 |
Association of the Clinical Subtype and Etiology for Delirium with the Outcome after Risperidone Monotherapy in Patients Having Cancer.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Checklist; Delirium; Female; Humans; Male; Middle Age | 2016 |
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Delirium; F | 2016 |
[Psychiatry and sleep disorders--delirium].
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; I | 2006 |